RxDoctor Payments DataLook up a doctor →

Jonathan Obert, MD

Gastroenterology · New Albany, INNPI 1063703007

Payments from drug & device makers

$758,112in general payments, 2019–2025

Across 1,076 payments — averaging $704.57 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Genentech, Inc.$224K
  • Phathom Pharmaceuticals, Inc.$179K
  • F. Hoffmann-la Roche AG$119K
  • Teva Pharmaceuticals USA, Inc.$83K
  • Takeda Pharmaceuticals U.S.A., Inc.$69K
  • Madrigal Pharmaceuticals$37K
  • plus $46K from 43 others
$938in research payments, 2019–2025

Across 6 payments — averaging $156.32 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • AbbVie$938

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$758,112 in reported general payments places this provider in the 95th percentile of 323 gastroenterology providers in Indiana.

See all gastroenterology providers in Indiana

Medicare billing

Part B allowed, 2024
$514,520
Medicare patients
765
Services billed
19,214

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other gastroenterology in New Albany

See the full list for Indiana

Where these figures come from

Is this you, or does something look wrong? →